B3 Pharma

B3 Pharma is a clinical-stage biotechnology company focused on developing novel small molecule therapies for metabolic disorders, including obesity and type 2 diabetes. The company's primary research centers on the activation of the beta-3 adrenergic receptor (ADRB3), a target known to regulate energy expenditure and improve insulin sensitivity. Their lead candidate, B3P-118, is a highly selective ADRB3 agonist designed to increase metabolic rate without the cardiovascular side effects associated with earlier generations of similar compounds. Founded by metabolic experts from the Pennington Biomedical Research Center, B3 Pharma leverages decades of expertise in thermogenesis and lipid metabolism. The company aims to provide safer pharmacological alternatives to address the global epidemic of metabolic syndrome.